FDA Approves Sirolimus Balloon for Stent Reblockage
The Selution SLR drug-eluting balloon is the first sirolimus-based device of its kind cleared in the US for coronary in-stent restenosis.
The FDA has cleared the Selution SLR drug-eluting balloon for treating coronary in-stent restenosis, Cordis announced Monday. The device is now the only sirolimus-based drug-eluting balloon available in the US for this indication, according to the company.
In-stent restenosis occurs when scar tissue grows inside a previously placed stent, narrowing the artery again. The Selution SLR balloon is designed to deliver a sustained release of sirolimus directly to the vessel wall during angioplasty, without adding another permanent metal layer.
The approval gives interventional cardiologists a new option for a challenging clinical problem, though the announcement did not include detailed trial data. The source notes the device's unique position as the sole sirolimus-based DEB in the US market, but does not compare it directly with existing paclitaxel-coated balloons.
Sources · 2
More in Medicine & Biotech
Rare Pregnancy Infections Linked to Autism and Intellectual Disability
A Karolinska Institutet study in JAMA Pediatrics finds that rare fetal infections are associated with higher risks of autism and intellectual disability.
Brain may be two fused organs, Stanford study suggests
New research indicates the human brain develops from two distinct cellular systems, hinting that evolution fused two ancient nervous systems.
Hidden Gut Defect in Remission May Explain IBD Relapses
A lingering molecular warning sign in gut tissue may explain why inflammatory bowel disease keeps returning.
AI turns unstructured clinical data into research-ready variables
A new analysis highlights how AI can help healthcare organizations convert fragmented, unstructured data into structured variables, addressing a major bottleneck in clinical research.